logo

For the Inventor, By the Inventor

Lexington, MA, United States of America

Curis, Inc.


USPTO Granted Patents = 141

% Expired Patents = 39.0



Trademarks = 2

Forward Citations = 1,468

Loading Chart...
Loading Chart...

142 inventors (with patents filed for the assignee):

goldMedal Xiong Cai (46 out of 73 patents)

silverMedal Changgeng Qian (43 out of 51 patents)

bronzeMedal Haixiao Zhai (36 out of 39 patents)

4.  Charles M Cohen (17 out of 60 patents)

5.  David C Rueger (16 out of 83 patents)

6.  Chengjung Lai (15 out of 15 patents)

7.  Oivin M Guicherit (15 out of 16 patents)

8.  Lee L Rubin (14 out of 32 patents)

9.  Hermann Oppermann (13 out of 88 patents)

10.  Stephen Colin Price (13 out of 55 patents)

11.  Roy H L Pang (13 out of 21 patents)

12.  Edward Andrew Boyd (13 out of 33 patents)

13.  Thangavel Kuberasampath (11 out of 67 patents)

14.  Kuber T Sampath (10 out of 46 patents)

15.  Stephen Gould (10 out of 10 patents)


Core Competencies:
Phosphoinositide 3-Kinase
Hedgehog Antagonists
HSP90 Inhibitors
Combination Therapy
Immunomodulators
Tyrosine Kinase Inhibitors
Quinazoline Inhibitors
Cell Proliferation Regulators
Crystalline Forms
Small Organic Molecules
RNA Interference
Cancer Therapy

141 patents:

1. 12403142 - Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety (2025-09-02),
2. 12252475 - Crystal forms of immunomodulators (2025-03-18),
3. 12178821 - Combination therapies for the treatment of cancer (2024-12-31),
4. 12064418 - Conjoint therapies for immunomodulation (2024-08-20),
5. 11939306 - Crystal forms of immunomodulators (2024-03-26),
6. 11654136 - Phosphoinositide 3-kinase inhibitor with a zinc binding moiety (2023-05-23),
7. 11643401 - Crystal forms of immunomodulators (2023-05-09),
8. 11597732 - Phosphoinositide 3-kinase inhibitors with a zinc binding moiety (2023-03-07),
9. 11497735 - Conjoint therapies for immunomodulation (2022-11-15),
10. 11261195 - Phosphoinositide 3-kinase inhibitors with a zinc binding moiety (2022-03-01),
11. 11234986 - Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety (2022-02-01),
12. 11135205 - Phosphoinositide 3-kinase inhibitor with a zinc binding moiety (2021-10-05),
13. 11040948 - Crystal forms of immunomodulators (2021-06-22),
14. 10894795 - Phosphoinositide 3-kinase inhibitors with a zinc binding moiety (2021-01-19),
15. 10844056 - Fused amino pyridine as HSP90 inhibitors (2020-11-24),
Company Overview
Curis, Inc. is a biotechnology company based in Lexington, Massachusetts, specializing in the development of innovative cancer treatments. The company focuses on advanced therapeutic modalities, including phosphoinositide 3-kinase inhibitors, Hedgehog antagonists, and HSP90 inhibitors. Curis is dedicated to addressing unmet medical needs in oncology through combination therapies and immunomodulators, aiming to improve patient outcomes in various cancer types. Its research emphasizes targeted therapies that regulate cell proliferation and enhance treatment efficacy.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Curis, Inc. USPTO Patent Assignee Logo
141 Patents

#5 in Lexington, MA

#148 in Massachusetts

#2,768 in US

#5,751 in the World

Lexington, MA (US)
Lexington, MA, United States of America

Curis, Inc.

Forward Citations = 1,468

142 inventors:

goldMedal Xiong Cai (46 out of 73 patents)

silverMedal Changgeng Qian (43 out of 51 patents)

bronzeMedal Haixiao Zhai (36 out of 39 patents)

4.  Charles M Cohen (17 out of 60 patents)

5.  David C Rueger (16 out of 83 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Curis, Inc.. Retrieved from https://idiyas.com/company/curis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…